Aspen Neuroscience, Inc.

S.Biomedics’ stem cell therapy for Parkinson’s disease has shown positive results in an assessment of one-year data from the three patients (first low-dose cohort) in a Phase I/IIa clinical trial, rai

Stock market investors may be holding back dollars from public biopharmaceutical firms as macroeconomic issues and other factors severely impact company valuations, but venture capital investment has

Even with less venture capital raised during the first quarter of 2022 than in Q1 of 2021, VC financing has become the most common type of financing for biopharmaceutical firms raising cash in 2022, a

Venture capital investors continue to show their enthusiasm for drug development, despite the relative pessimism of their peers investing in publicly traded biopharmaceutical companies, by putting the